Honz Pharmaceutical Co., Ltd. (SHE:300086)
China · Delayed Price · Currency is CNY 9.57
+0.15 (1.59%)
Feb 4, 2026, 3:05 PM CST
Honz Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 409.72 | 447.15 | 703.1 | 504.13 | 806.99 | 894.55 |
Other Revenue | 25.67 | 25.67 | 36.47 | 31.61 | 29.57 | 27.09 |
| 435.39 | 472.82 | 739.57 | 535.75 | 836.57 | 921.64 | |
Revenue Growth (YoY) | -33.19% | -36.07% | 38.05% | -35.96% | -9.23% | -8.61% |
Cost of Revenue | 208.24 | 225.36 | 298.27 | 269.35 | 418.41 | 451.93 |
Gross Profit | 227.15 | 247.46 | 441.3 | 266.4 | 418.16 | 469.71 |
Selling, General & Admin | 337.13 | 379.33 | 352.59 | 360.73 | 384.03 | 367.69 |
Research & Development | 11.44 | 19.05 | 18.68 | 28.44 | 14.7 | 16.57 |
Other Operating Expenses | 13.42 | 9.79 | 12.71 | 10.88 | 11.27 | 9.25 |
Operating Expenses | 351.45 | 404.18 | 386.46 | 413.05 | 423.52 | 402.77 |
Operating Income | -124.3 | -156.72 | 54.84 | -146.65 | -5.37 | 66.94 |
Interest Expense | -19.88 | -21.07 | -25.3 | -27.4 | -18.74 | -18.46 |
Interest & Investment Income | 0.17 | 17.52 | 2.86 | 2.8 | 56.94 | 4.82 |
Earnings From Equity Investments | - | - | - | -0.21 | - | - |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | 0.01 | -0.21 | 0.11 | 2.24 |
Other Non Operating Income (Expenses) | -3.96 | -5.82 | -1.21 | 3.27 | -5.49 | -2.92 |
EBT Excluding Unusual Items | -147.95 | -166.08 | 31.2 | -168.41 | 27.46 | 52.62 |
Impairment of Goodwill | -6.55 | -6.55 | - | - | -3.4 | - |
Gain (Loss) on Sale of Investments | -18.14 | -18.14 | -11.6 | -23.62 | -5.51 | 0.62 |
Gain (Loss) on Sale of Assets | 0.21 | -0.23 | 0.72 | 0.1 | 0.07 | -0.63 |
Asset Writedown | -27.27 | -38.7 | -2.12 | -28.55 | -0.39 | -0.1 |
Legal Settlements | - | - | - | - | -0.05 | -27.39 |
Other Unusual Items | -2.2 | -2.27 | 5.24 | -1.04 | 2.19 | 3.64 |
Pretax Income | -201.9 | -231.97 | 23.45 | -221.52 | 20.35 | 28.76 |
Income Tax Expense | -4 | -7.54 | 18.28 | -23.57 | 9.78 | 8.77 |
Earnings From Continuing Operations | -197.9 | -224.43 | 5.17 | -197.95 | 10.57 | 19.99 |
Minority Interest in Earnings | 7.81 | 8.22 | 6.36 | 10.37 | 0.42 | -10.65 |
Net Income | -190.09 | -216.21 | 11.53 | -187.58 | 10.99 | 9.34 |
Net Income to Common | -190.09 | -216.21 | 11.53 | -187.58 | 10.99 | 9.34 |
Net Income Growth | - | - | - | - | 17.65% | - |
Shares Outstanding (Basic) | 456 | 456 | 450 | 450 | 450 | 449 |
Shares Outstanding (Diluted) | 456 | 456 | 450 | 450 | 450 | 449 |
Shares Change (YoY) | 0.58% | 1.34% | 0.10% | -0.08% | 0.29% | -0.23% |
EPS (Basic) | -0.42 | -0.47 | 0.03 | -0.42 | 0.02 | 0.02 |
EPS (Diluted) | -0.42 | -0.47 | 0.03 | -0.42 | 0.02 | 0.02 |
EPS Growth | - | - | - | - | 17.31% | - |
Free Cash Flow | 15.24 | -21.04 | -66.87 | -29.57 | -208.64 | -316.31 |
Free Cash Flow Per Share | 0.03 | -0.05 | -0.15 | -0.07 | -0.46 | -0.70 |
Dividend Per Share | - | - | - | - | - | 0.020 |
Gross Margin | 52.17% | 52.34% | 59.67% | 49.72% | 49.98% | 50.97% |
Operating Margin | -28.55% | -33.15% | 7.41% | -27.37% | -0.64% | 7.26% |
Profit Margin | -43.66% | -45.73% | 1.56% | -35.01% | 1.31% | 1.01% |
Free Cash Flow Margin | 3.50% | -4.45% | -9.04% | -5.52% | -24.94% | -34.32% |
EBITDA | -72.86 | -94.15 | 132.27 | -96.41 | 33.61 | 117.06 |
EBITDA Margin | -16.73% | -19.91% | 17.88% | -18.00% | 4.02% | 12.70% |
D&A For EBITDA | 51.44 | 62.57 | 77.43 | 50.25 | 38.98 | 50.12 |
EBIT | -124.3 | -156.72 | 54.84 | -146.65 | -5.37 | 66.94 |
EBIT Margin | -28.55% | -33.15% | 7.41% | -27.37% | -0.64% | 7.26% |
Effective Tax Rate | - | - | 77.95% | - | 48.06% | 30.51% |
Revenue as Reported | 435.39 | 472.82 | 739.57 | 535.75 | 836.57 | 921.64 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.